http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Abdullah Ozkaya (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Abdullah Ozkaya,Zeynep Alkin,Mesut Togac,Sibel Ahmet,Irfan Perente,Muhittin Taskapili 대한안과학회 2017 Korean Journal of Ophthalmology Vol.31 No.5
Purpose: To evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration (nAMD) in a single center and real life clinical setting. Methods: The records of nAMD patients who were treated with ranibizumab between January 2010 and June 2011 were retrospectively reviewed. Patients who completed 5 years of follow-up were included. Main outcome measures were change in best-corrected visual acuity, central retinal thickness, and visit and injection numbers. Results: Forty-four eyes of 37 patients were included. Mean best-corrected visual acuity decreased from 0.82 ± 0.69 to 1.11 ± 0.65 logarithm of minimal angle of resolution after 5 years. Twenty-four eyes (54.5%) had visual acuity loss ≥3 lines, and 20 eyes (45.5%) had stable or improved vision (loss <3 lines, remained stable, or gained ≥1 line) at month 60. The mean total number of visits was 25.3 ± 5.8 (range, 14 to 42), and the mean total number of injections was 12.6 ± 6.4 (range, 3 to 26) at month 60. Conclusions: Half of the ranibizumab-treated nAMD patients maintained their vision during the 5 years of follow- up. Visit and injection numbers were found to be lower than in prospective studies, reflecting a real world clinical practice.
KCI
스콜라연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
